Pharma deals with disruptions at Egypt offices

Share this article:

Staffers have been sent home and security has been bolstered at pharma offices located in Egypt's capital city, amid protests in Tahrir Square that have turned violent in recent days.

Calls made early this morning to offices and subsidiaries located in Cairo and controlled by Novartis, Abbott, Roche and Merck were not answered, indicating that at least some workers had been sent home. “Our colleagues [at Merck's MSD Egypt office] are safe and are working from home, to the extent that they can,” said Steven Campanini, director of corporate media relations at Merck. Campanini said the turmoil in Cairo hasn't had any impact, “in terms of the business.”

An employee answering the phone at Sanofi-Aventis Egypt, located in Cairo, said the “company is OK…we have good security,” adding that a new security manager had been assigned to protect the company's offices. Stateside Sanofi reps did not immediately respond to a request for comment.

Novartis has several locations in Egypt, including pharmaceutical and consumer health divisions, as well as Sandoz, the company's generics manufacturer. Novartis' manufacturing operations in Egypt produce 75 million medicine packets per year, making it the company's seventh largest manufacturing center, according to the Novartis Egypt website."To date, all Novartis associates in the country are accounted for," said Julie Masow, a Novartis spokesperson, in an email. "Most of Novartis' premises in Egypt are closed, however, we are continuing essential operations to ensure the delivery of orders of life-saving products," she said.  

Ana Paula Barboza, director of public affairs at Abbott International, said in an email that Abbott's operations are continuing in Egypt. "Abbott is monitoring the situation closely from an employee safety perspective," she said.

Phil Deschamps, president and CEO at inVentiv Health's GSW Worldwide, said in an email that the company's inVentiv Health Intermark office, located in Cairo and “staffed with over 75 talented local Egyptian and Middle Eastern people,” has been unreachable. “We have been unable to communicate with our staff there since there is a virtual blackout in communications,” said Deschamps via email. “We are anxious to make sure our people are safe. We wish them well in what must be a very trying time for our staff and the people of Egypt."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...